Ventana PD-L1 (SP142) Assay

被引：0
|
作者：
McGill, Rachel [1 ]
Michail, Ramez [1 ]
Miller, Brianne [1 ]
Milton, Erica [1 ]
Musyoka, Agnes [1 ]
Musyoka, Rhoda [1 ]
O'Conner, Jada [1 ]
Ogunnaike, Morenike [1 ]
Omeke, Soteria [1 ]
Franklin, Gallop [1 ]
Honeywell, Marlon S. [1 ]
机构：
[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Inst Publ Hlth, Tallahassee, FL 32307 USA
来源：
US PHARMACIST | 2022年 / 47卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：42 / 44
页数：3
相关论文
共 50 条
  • [41] Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.
    Scott, Marietta L.
    Scorer, Paul
    Lawson, Nicola
    Ratcliffe, Marianne J.
    Barker, Craig
    Rebelatto, Marlon
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 830 - 831
  • [43] PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)
    Ma, Jing
    Li, Jianhui
    Qian, Meirui
    Han, Weili
    Tian, Miaomiao
    Li, Zengshan
    Wang, Zhe
    He, Shuixiang
    Wu, Kaichun
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [44] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio, Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 862 - 862
  • [45] THE CLINICAL AND ECONOMIC IMPACT OF PD-L1 SP142 ASSAY USING ATEZOLIZUMAB plus NPACLITAXEL IN THE PATHWAY OF PATIENTS WITH METASTATIC OR ADVANCED TRIPLE NEGATIVE BREAST CANCER
    Cattelino, L.
    Piccolo, F.
    Mauti, R.
    VALUE IN HEALTH, 2020, 23 : S449 - S449
  • [46] A UK wide survey of PD-L1 expression in triple negative breast cancers (TNBC) as assessed by SP142 assay and correlation with clinicopathological parameters and patient outcomes
    Warren, M.
    Linares, J.
    Khiroya, R.
    Marafioti, T.
    Mackie, S.
    Allen, D.
    HISTOPATHOLOGY, 2022, 81 : 30 - 31
  • [47] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio', Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 862 - 862
  • [48] Concordance of tumor cell (TC) and immune cell (IC) staining with Ventana SP142, Ventana SP263, Dako 28-8 and Dako 22C3 PD-L1 IHC tests in NSCLC patient samples.
    Scott, Marietta L.
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Barker, Craig
    Scorer, Paul
    Rebelatto, Marlon
    Al-Masri, Hytham
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Evaluation of NSCLC Cytology Cell Block Specimens Using Ventana PD-L1 SP263 Immunohistochemistry Assay
    Chauhan, Aastha
    Racila, Emilian
    Stewart, Jimmie
    Amin, Khalid
    LABORATORY INVESTIGATION, 2019, 99
  • [50] PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance
    Han, Eun Kyung
    Woo, Ji Won
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Jee Hyun
    Park, So Yeon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 557 - 566
12345